/DESIGN/newswire -- COMO, CO, ITALY -- THURSDAY, 21 NOVEMBER 2024, 10:19 UTC+1
HIGH RESOLUTION IMAGE AVAILABLE
CHINA -- /DESIGN/newswire -- Oct 23, 2023
SUIADR Unveils Innovative Industrial Park in Pingshan District, Shenzhen, China
FOR IMMEDIATE RELEASE
SUIADR introduces the groundbreaking Hepalink Industrial Park, a cutting-edge bio-pharmaceutical facility located in the eastern part of Pingshan District, Shenzhen City. The project, completed in August 2022, is set to revolutionize the bio-pharmaceutical industry in the region.
The campus, spanning approximately 20.48 hectares, is strategically positioned along the Modern Industry Development Axis of Pingshan, near Huizhou, serving as a vital link between the two districts. It is designed to be the largest biopharmaceutical industrial park in Pingshan, emphasizing independent functions, shared resources, and future adaptability for multifunctional purposes.
Designed to meet the specific production requirements of Hepalink, the facility boasts modular column grids, standardized floor heights, and reserved capacities for water, electricity, and wind equipment. This forward-thinking approach ensures seamless adaptability for multifunctional purposes and sets a new standard for bio-pharmaceutical facilities.
The project, which commenced in January 2018, represents a pioneering industrial park construction endeavor characterized by functional diversification, integration, and specialization. The design team's meticulous approach and innovative solutions have positioned Hepalink Industrial Park as a trailblazing development in the bio-pharmaceutical landscape.
Founded in 1984, SUIADR is a leading class-A design firm renowned for its influential architectural and urban planning projects. The completion of the Hepalink Industrial Park further solidifies SUIADR's reputation as a trailblazer in innovative and impactful design solutions.
-END-
Join our community of leading journalists and gain immediate access to premium content, in-depth design insights, and exclusive interviews and press releases.
Create Your Journalist Account